To summarize, our findings indicate that cathepsin O played a beneficial role in BPH, cathepsin X posed a potential risk for prostatitis, and prostatitis had an adverse impact on the expression of cathepsin V. These cathepsins may become new targets for future BPDs diagnosis and treatment, but further validation is needed. Here, CTSO is linked to benign prostatic hyperplasia.